Comparison the effect of Rosuvastatin and Atorvastatin on serum FGF23 level and renal klotho gene expression in hyperlipidemic male rats
MetadataShow full item record
The aim of the present study is to compare the reduction effects between Rosuvastatin and Atorvastatin on lipid profile, oxidative stress and to evaluate the possible increase in Klotho gene expression and kidney damage assessment. Methods: Forty male rats were divided into five groups of 8, including: normal control, sham, hypercholesterolemic control, HCD + Rosuvastatin (20 mg/kg/BW), HCD treatment + Atorvastatin (20 mg/kg/BW). The markers of oxidative stress, kidney damage and expression of the Klotho gene were evaluated in these groups. Results: Both Rosuvastatin and Atorvastatin significantly decreased the lipid profile indices including Low Density Lipoprotein Cholesterol (LDL-C), Total Cholesterol, Triglyceride, Very Low Density Lipoprotein Cholesterol (VLDL-C) and significantly increased High Density Lipoprotein Cholesterol (HDL-C) compared with hyperlipidemic control group(p<0.05). The efficacy of Rosuvastatin in reducing LDL-C serum levels was greater than Atorvastatin (p <0.01). Both Rosuvastatin and Atorvastatin significantly decreased serum levels of fibroblast growth factor 23 (p<0.01). But the most significant decreasing effects were observed in Atorvastatin treatment (p<0.01). Although serum levels and expression of the Klotho gene increased after treatment with both Rosuvastatin and Atorvastatin compared with hyperlipidemic control group (p<0.01), but Atorvastatin had more additive effects than Rosuvastatin (p<0.01).